Recent advances have led to a greater understanding of the role of cellular oncogenes and their products in carcinogenesis in man. ' 2 Activated cellular ras oncogenes have been found in several solid tumours,34
and their transforming ability on NIH 3T3 fibroblasts has been shown.5 They code for a group of cellular proteins (p21) thought to take part in normal proliferation,6 and increased expression of the ras oncogene family has been detected by hybridisation analysis in colorectal tumours.7 RAP-5 monoclonal antibody is directed against a synthetic peptide sequence, reflecting positions 10-17 of the human ras (Hu-ras) protein product (p21) derived from the T24 bladder carcinoma.8 It has been found to show differential ras gene expression in benign and malignant colonic disease. 9 A further aid to assessing malignant changes in colorectal mucosa has been the use of epithelial tissue markers by applying antibodies to carcinoembryonic antigen,'0 IgA secretory component,"1 and epithelial membrane antigen. 12 Monoclonal antibody CA19-9 reacts with a carbohydrate antigenic determinant identified as a sialylated lacto-Nfucopentaose. 1' It is closely related to epithelial membrane antigen and is found at the epithelial cell Accepted for publication 3 September 1986 surface. It has been shown immunohistochemically in pancreatic, gastric, and colonic tumours. '4 The purpose of this study was to assess the use of these antibodies as tissue markers in evolving and established cases of colorectal carcinoma.
Material and methods
The material in this study came from the files of this hospital. The tissues had been fixed in 4% aqueous formaldehyde, secondarily fixed in Helly's fluid, and processed to paraffin wax. The sections studied consisted of histologically normal mucosa from the most distant resection limit of non-colitic colorectal carcinomas, plus five rectal adenomatous polyps, three villous adenomas, five colorectal carcinomas, and carcinomas from nine patients with ulcerative colitis, also showing regenerative and dysplastic mucosal changes. The colitic mucosa was assessed for dysplasia using a standardised classification.15 16 Some of this material also formed the basis of a previous immunoperoxidase study using antibodies to carcinoembyronic antigen and the IgA secretory system.17
ANTIBODIES AND IMMUNOHISTOCHEMICAL TECHNIQUES
The RAP-S monoclonal antibody was a generous gift 158 from Dr J Schlom, NIH, Bethesda, USA. It was applied at varying dilutions between 1/15000 and 1/25000 to trypsinised and non-trypsinised sections. Blocking of non-specific binding of antibody to protein was achieved with ovalbumin 1% and bovine serum albumin. Hydrogen peroxide was used to diminish endogenous peroxidase activity. The NIH protocol, based on a standard avidin-biotin-complex immunoperoxidase procedure, was followed,"8 and colourisation obtained using diaminobenzidine substrate with a light haematoxylin counterstain. Further sections were stained using indirect immunoperoxidase'9 and a streptavidin-biotin peroxidase system.20 The CA19-9 monoclonal antibody (Histocis CA19-9) was obtained by courtesy of CIS Allen, Foster, Orchin, Biggart (UK) Ltd, and it was applied to sections undiluted using the manufacturer's recommended avidin-biotin immunoperoxidase kit. In addition, the indirect and streptavidin-biotin techniques were also used. Immunoperoxidase staining was graded qualitatively as light, moderate, or heavy.
Results

RAP-5 MONOCLONAL ANTIBODY
Epithelial staining using this antibody was of a diffuse distribution throughout the cell cytoplasm. There was no accentuation of positivity in the supranuclear Golgi zone, the cell apex, or along the luminal border. Global uniformity of staining was seen in the various about by encountering a cofactor event such as a chemical carcinogen, viruses, or radiation. Heightened ras gene expression has been described in hybridisation studies in colonic polyps and tumours.7 On tissue sections using a different monoclonal to ras p21 (Y1 3 259 Hu-ras Harvey) than the one presently studied, two groups of workers found variable staining in normal colorectal mucosa and carcinoma,21 22 with an increased intensity in adenomatous polyps.22 RAP-5 antibody has been described as showing preferential staining in human mammary and colonic carcinomas over benign inflammatory and dysplastic lesions in these tissues.8 9 Its expression has been postulated to correlate with the depth of colonic wall tumour invasion and in areas of severe epithelial dysplasia, indicating a relatively late event in malignant transformation.9 Our present study did not show differential staining of the various epithelial cell populations or between different levels of tissue in the same lesion. In contrast to the findings of other studies,89 we also noted strong staining of non-epithelial tissue components as seen previously in the colon2' and breast. 23 Ghosh et a123 recently reported similar findings to ours in a range of breast lesions. We must agree with their interpretation that either RAP-S detects a normal cell product not enhanced in carcinogenesis, or that it does not show the abnormal p21 product, derived from mutagenesis and oncogene activation, which is necessary for neoplasia. An explanation for the discrepancy in colorectal studies using the two p21 antibodies may be that RAP-S reacts on solid phase radioimmunoassay with both T24 Hu-ras and Hu-ras Harvey peptides, which show an amino acid difference at position 12 of the p21 molecule.89 This indicates RAP-5 reactivity with a group of p21 proteins, and therefore the detection of a specific mutant p21 product relevant to tumour formation is made less likely.23 This in no way excludes the role of ras genes in colonic carcinogenesis but does seem to indicate a limited use in our hands for monoclonal antibody RAP-S in diagnostic colorectal pathology.
Neoplasia tissue markers include the expression of oncofetal antigens (carcinoembryonic antigen) and the loss of normal cell function with the evolution of malignancy (IgA secretory system). An allied approach has been to raise antibodies against the immunodominant antigen on tumour cell surfaces. MC2 and MC424 and antibody to epithelial membrane antigen achieve this by showing cell surface carbohydrate oligosaccharides. Monoclonal antibody CA19-9 recognises a closely related fucosylated pentasaccharide, sialylated lacto-N-fucopentaose, developed by immunisation of BALB/c mice with a human cell line SW 1116, derived from a colorectal carcinoma.2526 Its main use has been as a serum tumour marker in upper gastrointestinal disease,27 28 and it has been shown in adenocarcinoma tissue sections of stomach, pancreas, and colon."4 The findings in this study confirmed positive CA 19-9 staining in 12 of 14 colonic carcinomas, although it was focal and light in eight of these 12. Epithelial dysplasia showed variable staining, being totally negative in nine premalignant polyps but giving patchy, light deposition in just over half of the regenerative and dysplastic cases of ulcerative colitis. It is possible that CA19-9, like carcinoembryonic antigen and epithelial mucins (personal observations DCA), may reflect not only dysplasia but also regeneration in ulcerative colitis,17 29 where cell turnover and proliferation is known to be increased. 30 The supranuclear and cell surface staining of CA19-9 also corresponds to the Golgi apparatus and cell apex localisation of carcinoembryonic antigen seen on ultrastructural study of a human colorectal adenocarcinoma cell line. 31 The explanation for the spectrum of staining found in similar histological changes within the mucosa remains unanswered. Thus the results for differential staining of these epithelial subtypes were less reliable than the 162 Allen, Foster, Orchin, Biggart previously used carcinoembryonic antigen and IgA secretory system markers.`7 Therefore, CAl9-9 cannot be recommended for diagnostic use in tracing the evolution of malignant changes in the colorectal mucosa, particularly as a basis for discrimination between regeneration and dysplasia in ulcerative colitis. The disparity in staining between non-colitic premalignant polyps and carcinoma is of interest, and further work needs to be done to assess its ability to indicate carcinomatous change within mucosal polyps. At present, CA19-9 may be of limited use to the histopathologist in established malignancy when used in combination with other markers (eg CEA) in confirming metastatic adenocarcinoma of gastrointestinal origin.
In the absence of reliable immunohistochemical markers of colonic regeneration, dysplasia, and carcinoma one can only recommend that the pathologist gains sufficient experience of the spectrum of possible histological changes in colorectal epithelium and that his judgment be refined by application of standardised classifications. '5 32 We are grateful to Dr J Schlom and CIS (UK) Ltd, for donating the antibodies used in this study. We thank Mr PW Hamilton for his advice and Mrs J Hammill, who typed the manuscript.
